Scientists from Bristol-Myers Squibb have launched their elective course as part of the Rutgers Toxicology training program. This course aims to provide students and postdocs with an understanding of the drug discovery and development paradigm, from target validation and lead optimization to the numerous preclinical studies conducted to ensure drug safety. Scientists will describe the stages of drug development and the timing of various safety studies and review The International Council for Harmonisation (ICH) safety guidelines that dictate the battery of studies needed for the safety testing of pharmaceuticals. Over 150 participants nationwide are participating in this outstanding and insightful course!
